DUBLIN, April 11, 2018 /PRNewswire/ -- United Neuroscience, Ltd., (UNS), today announced that it has signed
"We are committed to applying our Endobody technology in areas of great potential impact and working with researchers who are best positioned to accelerate development of therapeutics," stated Mei Mei Hu, chief executive officer of UNS. "It takes a many minds, a team, an ecosystem, to beat a disease as Alzheimer's. Working with leading researchers as Marc Diamond at The Center for Alzheimer's and Neurodegenerative Diseases at UT Southwestern will provide important data as we expand our clinical pipeline to include tau protein as a mechanistic target."
"UNS's innovative technology and the clinical progress they have demonstrated are very encouraging. We are very excited to use new ideas about tau structure to design therapies more rationally," added Marc Diamond, M.D., Director of the Center for Alzheimer's and Neurodegenerative Diseases at the University of Texas Southwestern Medical Center. "This is a unique opportunity to link fundamental structural biology, biochemistry and vaccine design to speed the development of innovative treatments."
"Finding the correct protein target is a key step in finding solutions for neurodegenerative disease," commented Ajay Verma, M.D., Ph.D., chief medical officer of UNS. "We are fortunate to work with leaders in the field of research in understanding tau pathology. Because of the potential for our technology to develop combination vaccines to multiple specific protein epitopes, we are particularly interested in exploring the role of tau-targeted therapeutics as a complementary mechanism to additional therapeutics in development such as our UB-311 program in Alzheimer's disease."
About United Neuroscience
United Neuroscience (UNS) is a clinical-stage biotech company dedicated to the development of best-in-class immunotherapeutics for the brain. A global company with offices in Ireland, Taiwan and the United States, UNS was founded to address the social and economic burden of Alzheimer's and other neurodegenerative diseases and seeks to rapidly advance candidates into and through clinical trials with the goal of delivering breakthrough treatments to patients. For more information please visit www.unitedneuroscience.com. Follow UNS on Twitter at https://twitter.com/UNSTechBio and on LinkedIn at www.linkedin.com/company/unitedneuroscience.
David Schull or Rich AllanRusso Partners, LLC(212) 845-4271(646) email@example.com firstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/united-neuroscience-and-university-of-texas-southwestern-medical-center-announce-collaboration-to-evaluate-endobody-vaccine-candidates-directed-at-tau-protein-for-the-treatment-and-prevention-of-alzheimers-disease-300628116.html
SOURCE United Neuroscience, Ltd.
Subscribe to our Free Newsletters!
Lazy eye or amblyopia occurs when sight in one eye is less than the other in early childhood due to ...
Tracheal or windpipe cancer is a rare cancer and its cause is unclear. The most common squamous ...
Tecovirimat can be used to treat smallpox disease in adult and pediatric patients who weigh at ...View All